Cargando…

Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report

BACKGROUND: Response to antidepressant therapy is highly variable among individuals. Pharmacogenomic (PGx) testing presents an opportunity to guide drug selection while optimizing therapy outcomes and/or decreasing the risk for toxicity. CASE PRESENTATION: A patient with multiple comorbidities, incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Toro-Pagán, N. M., Matos, A., Bardolia, C., Michaud, V., Turgeon, J., Amin, N. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772164/ https://www.ncbi.nlm.nih.gov/pubmed/35057765 http://dx.doi.org/10.1186/s12888-021-03659-4

Ejemplares similares

Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report
por: Del Toro-Pagán, Nicole Marie, et al.
Publicado: (2021)

Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report
por: Muhn, Selina, et al.
Publicado: (2022)

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism
por: Deodhar, Malavika, et al.
Publicado: (2021)

Sleep Disturbances and Phenoconversion in Patients with REM Sleep Behavior Disorder
por: Jo, Hyunjin, et al.
Publicado: (2021)

Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
por: Orso, Beatrice, et al.
Publicado: (2023)

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Bardolia, Chandni, et al.
Publicado: (2021)

Drug Interaction and Pharmacist
por: Ansari, JA
Publicado: (2010)

Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder
por: Ganapathy S., Ranjani, et al.
Publicado: (2022)

Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson’s Disease
por: Pizzolato, Katie, et al.
Publicado: (2021)

Dasatinib-induced nephrotic syndrome: a case of phenoconversion?
por: Mandac Rogulj, Inga, et al.
Publicado: (2019)

Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion
por: Gharaee-Kermani, Mehrnaz, et al.
Publicado: (2016)

Cardiovascular Risk Factors and Phenoconversion to Neurodegenerative Synucleinopathies in Idiopathic REM Sleep Behavior Disorder
por: Zolfaghari, Sheida, et al.
Publicado: (2022)

Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report
por: Jessop, Jayson P., et al.
Publicado: (2023)

CXC-Type Chemokines Promote Myofibroblast Phenoconversion and Prostatic Fibrosis
por: Gharaee-Kermani, Mehrnaz, et al.
Publicado: (2012)

The role of club cell phenoconversion and migration in idiopathic pulmonary fibrosis
por: Fukumoto, Jutaro, et al.
Publicado: (2016)

Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review
por: Klomp, Sylvia D., et al.
Publicado: (2020)

Cardiosomal microRNAs Are Essential in Post-Infarction Myofibroblast Phenoconversion
por: Morelli, Marco B., et al.
Publicado: (2019)

Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients
por: den Uil, Manon G., et al.
Publicado: (2023)

Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study “FARPRESTO”
por: Puligheddu, Monica, et al.
Publicado: (2022)

Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder
por: Mattioli, Pietro, et al.
Publicado: (2022)

Assessment of community pharmacists’ knowledge about drug-drug interactions in Jeddah, Saudi Arabia
por: Alorfi, Nasser M., et al.
Publicado: (2023)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication
por: de Jong, Laura M., et al.
Publicado: (2023)

Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder
por: Yoon, Eun Jin, et al.
Publicado: (2022)

Correction to: Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study “FARPRESTO”
por: Puligheddu, Monica, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition
por: Long, Tao, et al.
Publicado: (2021)

Utilizing Pharmacogenomics Results to Determine Opioid Appropriateness and Improve Pain Management in a Patient with Osteoarthritis
por: Pizzolato, Katie, et al.
Publicado: (2022)

Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs
por: Michaud, Veronique, et al.
Publicado: (2020)

Evaluation of community pharmacists’ knowledge about drug–drug interaction in Central Saudi Arabia
por: Alrabiah, Ziyad, et al.
Publicado: (2019)

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease
por: Macciardi, Fabio, et al.
Publicado: (2022)

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
por: Deodhar, Malavika, et al.
Publicado: (2020)

Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall
por: Russell, Joshua, et al.
Publicado: (2023)

Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs
por: Michaud, Veronique, et al.
Publicado: (2021)

Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
por: Smith, Matt K., et al.
Publicado: (2021)

Rapid-acting oral drug (Auvelity) for major depressive disorder
por: Khabir, Yumna, et al.
Publicado: (2022)

Food-drug interactions: Knowledge among pharmacists in Jordan
por: Zawiah, Mohammed, et al.
Publicado: (2020)

Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
por: Urakawa, Ryuta, et al.
Publicado: (2020)

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders
por: Wolff, Jan, et al.
Publicado: (2021)

Pharmacist's drug handbook.
Publicado: (2001)

Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder
por: Gaspar, Héléna A., et al.
Publicado: (2019)

Similarity and consistency assessment of three major online drug–drug interaction resources
por: Kontsioti, Elpida, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v9ibs9b9l7hnhn4512d395ejvg